(Q31048851)

17 August 2017

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment (English)

1 reference

17 August 2017

1 reference

10

Sibylle Loibl

0 references

Wilko Weichert

12

object named as

Wilko Weichert

0 references

Frederick Klauschen

11

object named as

Frederick Klauschen

0 references

Manfred Dietel

9

object named as

Manfred Dietel

1 reference

17 August 2017

3

Albrecht Stenzinger

1 reference

17 August 2017

2

Nicole Pfarr

1 reference

17 August 2017

5

Volker Endris

1 reference

17 August 2017

13

Carsten Denkert

1 reference

17 August 2017

Jan Budczies

1

1 reference

17 August 2017

Denise Treue

4

1 reference

17 August 2017

Fakher Ismaeel

6

1 reference

17 August 2017

Nikola Bangemann

7

1 reference

17 August 2017

Jens-Uwe Blohmer

8

1 reference

17 August 2017

language of work or name

English

0 references

publication date

17 February 2016

1 reference

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

11

1 reference

17 August 2017

13236-13247

1 reference

Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

HER2 testing: current status and future directions.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Emerging landscape of oncogenic signatures across human cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Comprehensive molecular portraits of human breast tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

An integrated semiconductor device enabling non-optical genome sequencing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Genome structural variation discovery and genotyping

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Quantitative analysis of diagnostic guidelines for HER2-status assessment

11 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

11 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

11 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4914355

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

25 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26910888

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26910888

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.7451

1 reference

17 August 2017

1 reference

17 August 2017

1 reference